Latest Biotechnology, Pharmaceutical and Healthcare News from Healio

05:42 EST 19th November 2017 | BioPortfolio

Here are the most relevant search results for "Healio" found in our extensive news archives from over 250 global news sources.

More Information about Healio on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Healio for you to read. Along with our medical data and news we also list Healio Clinical Trials, which are updated daily. BioPortfolio also has a large database of Healio Companies for you to search.

Showing News Articles 1–25 of 2,200+ from Healio

Saturday 18th November 2017

VIDEO: Pearls for controlling inflammation in dry eye

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Laura M. Periman, MD, discusses the management of inflammation in dry eye disease.

AMPK activator reduces glucose level in type 2 diabetes in phase 2a trial

A novel AMP-activated protein kinase activator showed glucose reduction and decreased cardiovascular risk factors in people with type 2 diabetes in a phase 2a trial, according to a press release from the drug’s developer.The first-in-class drug (O304, Betagenon/Baltic Bio) activates AMP-activated protein kinase (AMPK), which regulates energy balance. By activating this protein, the researchers a...

VIDEO: Flicker ERG a useful tool for anterior segment surgeons

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Mitchell A. Jackson, MD, discusses how he has implemented flicker ERG as a valuable tool in evaluating patients for cataract surgery.

Friday 17th November 2017

VIDEO: Avedro ups cross-linking for keratoconus coverage to 28 insurance carriers

NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Reza Zadno, PhD, vice chair and CEO of Avedro, discusses the company’s work to expand insurance coverage for cross-linking treatment for keratoconus, and he also updates the progress on clinical trials for other cross-linking treatments.

VIDEO: Avedro updates cross-linking trials for low myopia, presbyopia, customized keratoconus

NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Rajesh K. Rajpal, MD, chief medical officer for Avedro, discusses the progress the company is making in Europe with clinical trials for the treatment of low myopia, presbyopia and customized cross-linking for keratoconus.

Secukinumab demonstrates sustained response, consistent safety profile in AS

SAN DIEGO — Secukinumab provided sustained improvements in signs and symptoms of ankylosing spondylitis among patients who completed three years of treatment, according to data presented at the American College of Rheumatology Annual Meeting.In addition to sustained improvements in physical function at 3 years, secukinumab also demonstrated a safety profile consistent with previous data for this...

Nearly 1 in 7 patients with diabetes have poor glycemic control

About one in seven patients with diabetes had poor glycemic control between 2007 and 2014 despite an increase in the frequency of self-reported testing and patient awareness of hemoglobin A1c, according to data published in JAMA.“In 2014, an estimated 30.3 million people (9.4%) in the United States had diabetes. Improving glycemic control reduces the risk of diabetes-related vascular complicatio...

ETDRS, ultra-widefield imaging on par for identifying retinopathy severity

Lloyd P. AielloNEW ORLEANS — In a baseline data review, ETDRS and ultra-widefield imaging appear comparable for determining diabetic retinopathy severity within the ETDRS fields, according to results of the ongoing Diabetic Retinopathy Clinical Research Network Protocol AA trial presented here.“There is moderate to substantial agreement between ETDRS photos and ultra-widefield images masked to...

VIDEO: Aura hopes to bring first ocular melanoma treatment to fruition

NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Elisabet de los Pinos, PhD, CEO of Aura Biosciences, discusses the work the company is doing to bring its treatment for ocular melanoma using viral nanoparticle conjugates to the U.S.

Rheumatology, Managed Care and Burnout

I recently chaired a CME program in Chicago, where I asked a polling question about which “obstacle” was the greatest impediment for effective patient care. Many of the usual suspects were among the responses, such as time crunches, hassles with electronic medical records, patient engagement and adherence issues, and keeping up with the literature, as well as insurance and financial challenges...

Treatment of Giant Cell Arteritis With Tocilizumab: A Historical Perspective

I am thrilled to have Gary S. Hoffman, MD, MS, MACR, write this month’s Guest Editorial for Healio Rheumatology. No one, in my judgment, is better qualified to help us consider how the recent advances in giant cell arteritis will ultimately effect the way we treat the disease and, of course, ultimately how our patients can potentially benefit from these changes. New therapies must be critically ...

Managing Care and Cost in a Profit-driven System

Clinicians who treat patients with rheumatologic diseases are facing an ever-growing set of non-clinical challenges. The issue at hand is managed care, and the crux of the problem is that the U.S. health care system has grown increasingly cumbersome and complex, forcing clinicians to spend more time dealing with bureaucracy and less time working toward patient outcomes. Moreover, some experts beli...

Diagnosis and Treatment of Pemphigus Vulgaris: Strategies for Optimal Multidisciplinary Care

A 37-year-old woman presents with oral lesions consistent with pemphigus vulgaris and is treated with prednisone 1 mg/kg daily in combination with methotrexate 15 mg/week. Although she initially responds to treatment, any attempt to decrease or taper dose is met with disease flare. After 13 months on treatment, her symptoms return, with new oral lesions and blistering on the upper back. She is ini...

SLE linked with increased atherosclerotic risk in early disease stages

According to findings, systemic lupus erythematosus appears to increase atherosclerotic risk in its early phase, while traditional risk factors have a greater impact on atherosclerosis during the later stages of SLE.In the study, researchers evaluated 210 women with SLE and 138 healthy controls who were enrolled in the Toronto Risk Factor Study. The Toronto Risk Factor Study began in 1998 and enro...

Thursday 16th November 2017

Micro-dosing of phenylephrine comparable to conventional dropper administration

Piezo-ejection micro-dosing of phenylephrine showed comparable results to traditional eyedropper administration in pupil dilation, as well as less systemic absorption, according to a study.The phase 2, masked, nonrandomized, crossover study evaluated pupil dilation with topical phenylephrine in 12 eyes of 12 patients administered by a conventional 32-µL eyedropper (2.5% or 10% formulation) and in...

Discontinuation of postmenopausal hormone therapy elevates cardiac, stroke death risk

In the first year after discontinuation of postmenopausal hormone therapy, the risk for cardiac and stroke death increases, particularly among women aged younger than 60 years, according to findings published in Menopause.“Associations between the long-term use of postmenopausal hormone therapy and risks of cardiovascular diseases have been studied for decades. The data are not uniform, perhaps ...

Monoclonal antibody shown to be safe, effective in managing PsA

SAN DIEGO – Treatment with ABBV-066, a monoclonal antibody that inhibits interleukin-23, provided substantial improvements in joint and skin scores among patients with psoriatic arthritis, according to findings presented at the American College of Rheumatology Annual Meeting.In addition, no novel or surprising side effects were observed with ABBV-066 (risankizumab, AbbVie) in this double-blind, ...

VIDEO: Novaliq aims for water-free drop drug delivery to improve safety, tolerability

NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Christian Roesky, PhD, managing director and CEO of Novaliq, discusses the company’s research into combining pharmaceuticals with its water-free EyeSol technology for enhanced drug delivery to the eye.

VIDEO: CheckedUp announces 15% growth in ophthalmology practices

NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Richard Awdeh, MD, CEO and founder of CheckedUp, discusses the company’s growth in uptake of its products in ophthalmology practices.

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

Scott GottliebWASHINGTON — When diagnosed with Hodgkin lymphoma at the age of 33 years, FDA Commissioner Scott Gottlieb, MD, was told he had a 90% chance of survival.“Ninety percent doesn’t sound so good if it’s you,” Gottlieb, now 44, told HemOnc Today following a keynote presentation at the Friends of Cancer Research Annual Meeting. “So, to me, that 10% sounded pretty grim.”Gottlie...

Dropless cataract surgery offers cheaper price but possible disadvantages

NEW ORLEANS — Dropless cataract surgery is cheaper for the patient and the health care system, but compounding issues and adverse events may be problematic, according to a speaker here.“Are these downsides to dropless surgery worth it? There are compounding issues, clearly. Triamcinolone has crystals, so they can cause floaters. Will you damage the zonules? Will it cause intraocular pressure s...

GI Dynamics loses CE mark, right to sell device for obesity, diabetes in EU

Medical device company GI Dynamics announced its CE Mark for EndoBarrier, an endoscopic alternative to bariatric surgery, has been rescinded by its notified body SGS due to quality management issues.As a result, the company can no longer sell the device in the European Union.“The company is evaluating its options including grounds for appeal of the decision, consulting with its advisors and has ...

Severe hot flashes heighten risk for obstructive sleep apnea

Midlife women experiencing severe or very severe hot flashes or night sweats have a greater risk for obstructive sleep apnea than those with mild or no vasomotor symptoms, according to findings published in Menopause.“The menopausal transition is independently associated with poor sleep and seems to be associated with increased risk for obstructive sleep apnea,” Catherine C. Gao, BA, from the ...

Study shows implant safe in postcataract inflammation

IVeena Delivery Systems announced positive results from a pilot trial for its bioerodible implant for treatment of pain and inflammation after cataract surgery.The implant, IVMED-10, is placed during cataract surgery and releases dexamethasone for 2 weeks. In the trial, eight patients were implanted with IVMED-10. The device was found to be safe and effective for control of inflammation, and retin...

VIDEO: Luxturna looks to be first gene therapy for retinal disease in US

NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Paulo Falabella, MD, medical affairs ophthalmic lead at Spark Therapeutics, discusses the company’s progress with getting Luxturna gene therapy approved for use in the U.S.

Quick Search

News Quicklinks